Derivation of pancreatic islet-like organoids from human gastric stem cells

从人胃干细胞中衍生胰岛样类器官

基本信息

  • 批准号:
    10502451
  • 负责人:
  • 金额:
    $ 60.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-24 至 2026-05-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Islet transplantation offers a potential cure for Type 1 diabetes (T1D). Wide adoption of this promising therapy requires abundant islet supplies and effective immune protection. My laboratory and others showed that it was feasible to derive insulin-secreting cells from gastrointestinal (GI) tissues. However, it has not been possible to mass-produce islet-like organoids from human GI tissues for detailed assessment of their translational potential. In preliminary studies, we established methods to culture human gastric stem cells (hGSCs) from biopsy or autopsy samples that can be expanded to billions. We developed a scalable 2-step method to produce thousands of GINS (Gastric Insulin Secreting) organoids by transient activation of NGN3 and stable expression of PDX1 and MAFA (collectively referred to as NPM factors). GINS organoids acquired glucose-stimulated-insulin-secretion (GSIS) within 10 days, and upon transplantation, rapidly reversed diabetes in mice and maintained normoglycemia for over 3 months, with no tumor formation. Human GINS organoids thus have favorable attributes as a potential cell product for T1D treatment. GINS organoids contain 25% of cells that closely resemble pancreatic E-cells but a paucity of GCG+ and SST+ cells. Human islets have 50-75% E-cells, 25-35% D-cells, and 5% G-cells. Both D- and G- cells exert paracrine effects on E-cell section. In this project, we aim to develop new clonal hGSC lines and novel nanoparticle-based mRNA transduction method suitable for mass production of organoids that closely mimic human islets in cell composition and function. These studies are based on preliminary data indicating that hGSC clonal lines are markedly different, with some predominantly producing E-like or D-/G-like cells. Their differentiated progenies can thus be combined to yield islet- like organoids. We will further study the clonal lines for chromatin features and PDX1/MAFA genomic binding to gain mechanistic insight in GINS formation. Together, these studies constitute a major step in advancing the long-term goal of developing GINS organoids for T1D treatment.
项目总结 胰岛移植为1型糖尿病(T1D)提供了一种潜在的治疗方法。广泛采用这一前景看好的 治疗需要充足的胰岛供应和有效的免疫保护。我的实验室和其他人 结果表明,从胃肠道组织中分离出胰岛素分泌细胞是可行的。 然而,目前还不可能从人的胃肠道组织中大规模生产胰岛样有机化合物 对其翻译潜力的详细评估。 在初步研究中,我们建立了培养人胃干细胞的方法。 活组织检查或尸检样本可以扩大到数十亿。我们开发了一种可扩展的两步法 通过瞬时激活NGN3产生数千种胃胰岛素分泌类有机物 以及PDX1和MAFA的稳定表达(统称为NPM因子)。杜松子酒有机化合物 10天内获得葡萄糖刺激胰岛素分泌(GSIS),并在移植后, 小鼠糖尿病迅速逆转,血糖维持在正常水平3个月以上,无肿瘤 队形。因此,人参皂苷类有机化合物具有作为T1D潜在细胞产物的有利属性 治疗。 GINS类有机化合物含有25%与胰腺E细胞相似的细胞,但缺乏GCG+ 和SST+细胞。人的胰岛有50%-75%的E细胞,25%-35%的D细胞和5%的G细胞。D-和G- 细胞在E细胞切片上发挥旁分泌作用。在本项目中,我们的目标是开发新的克隆性hGSC 适于大规模生产的线型和新型纳米颗粒信使核糖核酸转导方法 在细胞组成和功能上与人类胰岛非常相似的有机化合物。这些研究是基于 根据初步数据显示,HGSC克隆系明显不同,其中一些主要是 产生类E细胞或类D/G细胞。因此,它们分化出的后代可以组合成胰岛- 就像有机体一样。我们将进一步研究染色质特征和PDX1/MAFA基因组的克隆系 在杜松子酒形成过程中获得机械洞察力的约束。这些研究共同构成了重要的一步。 在推进开发用于T1D治疗的GINS有机化合物的长期目标方面。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Qiao Joe Zhou其他文献

Qiao Joe Zhou的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Qiao Joe Zhou', 18)}}的其他基金

Engineering islet-like organoids from gastric stem cells for T1D cell replacement therapy
从胃干细胞中改造胰岛样类器官,用于 T1D 细胞替代疗法
  • 批准号:
    10704110
  • 财政年份:
    2022
  • 资助金额:
    $ 60.21万
  • 项目类别:
Derivation of pancreatic islet-like organoids from human gastric stem cells
从人胃干细胞中衍生胰岛样类器官
  • 批准号:
    10689788
  • 财政年份:
    2022
  • 资助金额:
    $ 60.21万
  • 项目类别:
Engineering islet-like organoids from gastric stem cells for T1D cell replacement therapy
从胃干细胞中改造胰岛样类器官,用于 T1D 细胞替代疗法
  • 批准号:
    10512923
  • 财政年份:
    2022
  • 资助金额:
    $ 60.21万
  • 项目类别:
Investigating a master regulator of large intestine stem cells
研究大肠干细胞的主调节因子
  • 批准号:
    10458677
  • 财政年份:
    2021
  • 资助金额:
    $ 60.21万
  • 项目类别:
Investigating a master regulator of large intestine stem cells
研究大肠干细胞的主调节因子
  • 批准号:
    10298777
  • 财政年份:
    2021
  • 资助金额:
    $ 60.21万
  • 项目类别:
Investigating a master regulator of large intestine stem cells
研究大肠干细胞的主调节因子
  • 批准号:
    10671584
  • 财政年份:
    2021
  • 资助金额:
    $ 60.21万
  • 项目类别:
Generating novel sources of functional human insulin-secreting cells for T1D modeling
为 T1D 建模生成功能性人胰岛素分泌细胞的新来源
  • 批准号:
    9459621
  • 财政年份:
    2017
  • 资助金额:
    $ 60.21万
  • 项目类别:
Generating novel sources of functional human insulin-secreting cells for T1D modeling
为 T1D 建模生成功能性人胰岛素分泌细胞的新来源
  • 批准号:
    9849886
  • 财政年份:
    2017
  • 资助金额:
    $ 60.21万
  • 项目类别:
Reprogram gastric tissue to functional insulin-secreting cells
将胃组织重新编程为功能性胰岛素分泌细胞
  • 批准号:
    9916632
  • 财政年份:
    2016
  • 资助金额:
    $ 60.21万
  • 项目类别:
Reprogram gastric tissue to functional insulin-secreting cells
将胃组织重新编程为功能性胰岛素分泌细胞
  • 批准号:
    9221317
  • 财政年份:
    2016
  • 资助金额:
    $ 60.21万
  • 项目类别:

相似海外基金

WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 60.21万
  • 项目类别:
    Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 60.21万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 60.21万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 60.21万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 60.21万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 60.21万
  • 项目类别:
    EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 60.21万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 60.21万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 60.21万
  • 项目类别:
    Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 60.21万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了